Role of protease-activated receptors in airway function: a target for therapeutic intervention?

被引:68
作者
Lan, RS
Stewart, GA
Henry, PJ [1 ]
机构
[1] Univ Western Australia, QEII Med Ctr, Dept Pharmacol, Perth, WA 6009, Australia
[2] Univ Western Australia, Dept Microbiol, Div Inflammat & Infect Dis, Perth, WA 6009, Australia
[3] Univ Western Australia, QEII Med Ctr, Western Australian Inst Med Res, Perth, WA 6009, Australia
关键词
airway inflammation; asthma; Cytoprotection; PAR; protease; thrombin receptor;
D O I
10.1016/S0163-7258(02)00237-1
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Protease-activated receptors (PARs) are G-protein-coupled, seven transmembrane domain receptors that act as cellular enzyme sensors. These receptors are activated by the proteolytic cleavage at the amino terminus, enabling interaction between the newly formed "tethered ligand" and the second extracellular loop of the receptor to confer cellular signalling. PARs can also be activated by small peptides that mimic the tethered ligand. In the respiratory tract, PARs may be regulated by endogenous proteases, such as airway trypsin and mast cell tryptase, as well as exogenous proteases, including inhaled aeroallergens such as those from house dust mite faecal pellets. Immunoreactive PARs have been identified in multiple cell types of the respiratory tract, and PAR activation has been reported to stimulate cellular mitogenesis and to promote tissue inflammation. Activation of PARs concurrently stimulates the release of bronchorelaxant and anti-inflammatory mediators, which may serve to induce cytoprotection and to minimise tissue trauma associated with severe chronic airways inflammation. Furthermore, airway inflammatory responses are associated with increased epithelial PAR expression and elevated concentrations of PAR-activating, and PAR-inactivating, proteases in the extracellular space. On this basis, PARs are likely to play a regulatory role in airway homeostasis, and may participate in respiratory inflammatory disorders, such as asthma and chronic obstructive pulmonary disease. Further studies focussing on the effects of newly developed PAR agonists and antagonists in appropriate models of airway inflammation will permit better insight into the role of PARs in respiratory pathophysiology and their potential as therapeutic targets. (C) 2002 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:239 / 257
页数:19
相关论文
共 218 条
[1]   Inhibition of cellular action of thrombin by N3-cyclopropyl-7-{[4-(1-methylethyl)phenyl]methyl}-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine (SCH 79797), a nonpeptide thrombin receptor antagonist [J].
Ahn, HS ;
Foster, C ;
Boykow, G ;
Stamford, A ;
Manna, M ;
Graziano, M .
BIOCHEMICAL PHARMACOLOGY, 2000, 60 (10) :1425-1434
[2]   Mast cell tryptase stimulates human lung fibroblast proliferation via protease-activated receptor-2 [J].
Akers, IA ;
Parsons, M ;
Hill, MR ;
Hollenberg, MD ;
Sanjar, S ;
Laurent, GJ ;
McAnulty, RJ .
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 2000, 278 (01) :L193-L201
[3]  
Al-Ani B, 1999, J PHARMACOL EXP THER, V290, P753
[4]   Proteinase activated receptor 2: role of extracellular loop 2 for ligand-mediated activation [J].
Al-Ani, B ;
Saifeddine, M ;
Kawabata, A ;
Hollenberg, MD .
BRITISH JOURNAL OF PHARMACOLOGY, 1999, 128 (05) :1105-1113
[5]   An assay for high-sensitivity detection of thrombin activity and determination of proteases activating or inactivating protease-activated receptors [J].
Altrogge, LM ;
Monard, D .
ANALYTICAL BIOCHEMISTRY, 2000, 277 (01) :33-45
[6]  
Andrade-Gordon P, 2001, J PHARMACOL EXP THER, V298, P34
[7]   Design, synthesis, and biological characterization of a peptide-mimetic antagonist for a tethered-ligand receptor [J].
Andrade-Gordon, P ;
Mayanoff, BE ;
Derian, CK ;
Zhang, HC ;
Addo, MF ;
Darrow, AL ;
Eckardt, AJ ;
Hoekstra, WJ ;
McComsey, DF ;
Oksenberg, D ;
Reynolds, EE ;
Santulli, RJ ;
Scarborough, RM ;
Smith, CE ;
White, KB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (22) :12257-12262
[8]   Protective effect of a thrombin receptor (protease-activated receptor 1) gene polymorphism toward venous thromboembolism [J].
Arnaud, E ;
Nicaud, V ;
Poirier, O ;
Rendu, F ;
Alhenc-Gelas, M ;
Fiessinger, JN ;
Emmerich, J ;
Aiach, M .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2000, 20 (02) :585-592
[9]  
Arnaud E, 2000, THROMB HAEMOSTASIS, V84, P722
[10]  
Babu KS, 2000, CHEST, V118, P1470, DOI 10.1378/chest.118.5.1470